Uremic Pruritus Pipeline Insight

DelveInsight’s, “Uremic Pruritus Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Uremic Pruritus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Uremic Pruritus Understanding

Uremic Pruritus: Overview

Uremic Pruritus, also known as chronic kidney disease- associated pruritus (CKD-aP) is more of a symptom associated with advanced or end-stage renal disease that adversely affects the quality of life of patients. It has been reported that more than 40% of people undergoing hemodialysis experience uremic pruritus.


Symptoms

Symptoms associated with uremic pruritus are the daily bouts of itching that worsen at night and may hinder sleep. The itch may mostly be localized to one part of the body such as head, back, abdomen, and/or arms. The skin may look normal or present with xerosis marked with multiple sores or marks.


Diagnosis

Uremic pruritus is diagnosed as the itch directly related to kidney disease and with the absence of any other comorbid conditions to associate with the itching. Uremic pruritus may have variable presentation, which may be difficult to diagnose.


Treatment

The treatment of uremic pruritus may include to optimize the dialysis efficacy first to reduce serum parathyroid hormone to reduce the amount of phosphorous/calcium. Dry skin can be taken care of by the application of emollients and non-soap cleaners. UVB phototherapy and prescription of some drugs may also be done.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Uremic Pruritus R&D. The therapies under development are focused on novel approaches to treat/improve Uremic Pruritus.

Uremic Pruritus Emerging Drugs Chapters

This segment of the Uremic Pruritus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Uremic Pruritus Emerging Drugs


CR845: Cara Therapeutics

CR845, also known as KORSUVA, is in the preregistration phase of the drug development process. The drug belongs to the class of kappa opioid receptor agonists to treat the itch associated with uremic pruritus in a new way. KORSUVA IV has shown positive results in phase III trials and the efficacy of the same drug in the tablet form is being tested in the Phase II trial for non-hemodialysis patients.


LT 5001: Lumosa Therpaeutics

Lumos Therapeutics’ LT 5001, is a drug candidate for uremic pruritus. The drug has received Taiwan FDA approval for conducting Ib/2 trial. It is being developed to be applied topically. It is a partial mu-opioid antagonist and kappa-opioid agonist. The formulation is thought to have the ability to modulate opioid receptors that are there on immune cells and sensory nerves.

Further product details are provided in the report……..

Uremic Pruritus: Therapeutic Assessment

This segment of the report provides insights about the different Uremic Pruritus drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Uremic Pruritus

There are approx. 4+ key companies which are developing the therapies for Uremic Pruritus. The companies which have their Uremic Pruritus drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Cara Therapeutics and others.

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

  • Late-stage products ( Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Uremic Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Uremic Pruritus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Uremic Pruritus therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Uremic Pruritus drugs.

Uremic Pruritus Report Insights

  • Uremic Pruritus Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Uremic Pruritus Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Uremic Pruritus drugs?
  • How many Uremic Pruritus drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Uremic Pruritus?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Uremic Pruritus therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Uremic Pruritus and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Uremic Pruritus: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • •Assessment by Stage and Molecule Type

Uremic Pruritus – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Uremic Pruritus companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Uremic Pruritus Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

CR845: Cara Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

LT 5001: Lumosa Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Uremic Pruritus Key Companies

Uremic Pruritus Key Products

Uremic Pruritus- Unmet Needs

Uremic Pruritus- Market Drivers and Barriers

Uremic Pruritus- Future Perspectives and Conclusion

Uremic Pruritus Analyst Views

Uremic Pruritus Key Companies

Appendix

List of Table

Table 1: Total Products for Uremic Pruritus

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Uremic Pruritus

Figure 2: Late Stage Products                               

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Cara Therapuetics

• Lumosa Therapeutics

Forward to Friend

Need A Quote